1,4-dibenzyl-[1,4]diazepane-5,7-dione | 14288-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 1,4-dibenzyl-[1,4]diazepane-5,7-dione
• 英文别名: 1,4-dibenzyl-tetrahydro-[1,4]diazepine-5,7-dione；1,4-Dibenzyl-tetrahydro-[1,4]diazepin-5,7-dion；1,4-Dibenzyl-1,4-diazepane-5,7-dione
• CAS: 14288-16-5
• 化学式: C₁₉H₂₀N₂O₂
• mdl: MFCD02219508
• 分子量: 308.38
• InChiKey: YTRPKDXWJSGDKS-UHFFFAOYSA-N

物化性质

• 熔点：
  172-174 °C(Solv: benzene (71-43-2))
• 沸点：
  566.2±50.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.263
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N,N'-二苄基乙二胺 在 二氧化三碳 作用下， 生成 1,4-dibenzyl-[1,4]diazepane-5,7-dione
  参考文献：
  名称：

  Pauw, Recueil des Travaux Chimiques des Pays-Bas, 1936, vol. 55, p. 218

  摘要：

  DOI：

文献信息

• Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20020161001A1

  公开（公告）日：2002-10-31

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity

  本发明涉及治疗活性和选择性抑制剂酶DPP-IV，包含该化合物的药物组合物以及利用这些化合物制造用于治疗与DPP-IV使蛋白质失活有关的疾病的药物，例如2型糖尿病和肥胖症，以及治疗与DPP-IV使蛋白质失活有关的疾病的方法，例如2型糖尿病和肥胖症。
• Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：NOVO NORDISK A/S

  公开号：EP1561752A1

  公开（公告）日：2005-08-10

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.

  本发明涉及具有治疗活性和选择性的DPP-IV酶抑制剂、包含这些化合物的药物组合物、使用这些化合物治疗与DPP-IV灭活的蛋白质有关的疾病（如2型糖尿病和肥胖症）的药物以及治疗与DPP-IV灭活的蛋白质有关的疾病（如2型糖尿病和肥胖症）的方法。
• Stankiewicz; Bobranski; Tatarczynska, Farmaco, Edizione Scientifica, 1984, vol. 39, # 12, p. 1038 - 1049
  作者：Stankiewicz、Bobranski、Tatarczynska、Chojnacka-Wojcik

  DOI：——

  日期：——
• STANKIEWICZ, K.;BOBRANSKI, B.;TATARCZYNSKY, E.;CHOJNACKA-WOJCIK, E., FARMACO. ED. SCI., 1984, 39, N 12, 1038-1049
  作者：STANKIEWICZ, K.、BOBRANSKI, B.、TATARCZYNSKY, E.、CHOJNACKA-WOJCIK, E.

  DOI：——

  日期：——
• PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV)
  申请人：NOVO NORDISK A/S

  公开号：EP1301187B1

  公开（公告）日：2005-07-06